PODCAST: Corruption at a major policy bank, and AbbVie sues an upstart drug maker
China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
RELATED ARTICLES
-
Yibin Bank’s IPO spotlights challenges facing regional lenders
2596.HK -
New solar policy support, and a stock market cleanup
DQ.US 688303.SHG
-
BRIEF: China Renaissance founder Bao Fan being probed for corruption
1911.HK
-
Operating at just half capacity, Daqo looks to Beijing for policy support
DQ.US 688303.SHG
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
